Articles with keyword mutations
-
Prognostic significance of longitudinal evaluation on egfr mutant ctdna during tki treatment in nsclc
F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rjsev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, N.H. Abduloeva, V.V. Egorenkov, V.M. Moiseyenko
mutations, EGFR, tumor, ctDNA, therapy.
-
Advances in fundamental oncology: the year 2020 update
E.N. Imyanitov
Genes, mutations, gene expression, predictive markers.
-
Advances in fundamental oncology: the year 2021 update
E.N. Imyanitov
Genes, mutations, gene expression, predictive markers
-
Advances in fundamental oncology: the year 2022 update
E.N. Imyanitov
Genes, mutations, gene expression, predictive markers.
-
Relationship between molecular genetic and clinical and morphological parameters in patients with stage i–iiia non-small cell lung cancer
А.М. Kazakov, К.К. Laktionov, К.А. Sarantseva, М.G. Gordiev
targeted sequencing, somatic mutations, non-small cell lung cancer
-
MOLECULAR-ORIENTED AND PRECISION CANCER THERAPY – THE PRESENT AND FUTURE ASPECTS
D.B. Korman
cancer, molecular-oriented drugs, precision therapy, sequencing DNA, tumor-associated mutations, tumor-type agnostic therapy.
-
EVOLUTION OF SCREENING FOR PROSTATE CANCER
A.I. Novikov
prostate cancer, screening, prostate-specific antigen (PSA), prostate health index, multiparameter magnetic-resonance tomography (mpMRI), biomarkers (Select MDX, HOXX6, DLX1), genetic mutations (BRCA1/2, HOXB13).
-
Neurooncology
D.E. Matskо, M.V. Matsko, E.N. Imyanitov
classification of CNS tumors, the degree of malignancy of the central nervous system tumors, molecular genetics, mutations in the gene IDH1/2, the co-deletion 1p19q, neurooncology